About UCSF Search UCSF UCSF Medical Center

Nola M. Hylton, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
hylton_nola

Professor in Residence, Department of Radiology, UCSF; and Director, Magnetic Resonance Science Center

Nola.Hylton@radiology.ucsf.edu

Phone: (415) 476-8856, 476-9023 (voice)
Box 1290, UCSF
San Francisco, CA 94143-1290

View on UCSF Profiles


Education

Massachusetts Institute of Technology (M.I.T.), B.S., 1979, Chemical Engineering
Stanford University, Ph.D., 1985, Applied Physics

Professional Experience

  • 6/76-8/76
    Technical Associate, Bell Telephone Laboratories, Murray Hill, N.J.
  • 6/77-8/77
    Research Assistant, Bell Telephone Laboratories, Murray Hill, N.J.
  • 6/78-8/78
    Research Assistant, Bell Telephone Laboratories, Murray Hill, N.J.
  • 9/79-12/82
    Research Assistant, E. L. Ginzton Laboratory, Stanford University, Stanford,California
  • 1/83-12/84
    Research Assistant, Radiologic Imaging Laboratory, Department of Radiology, University of California, San Francisco
  • 1/85-7/92
    Assistant Professor, Radiologic Imaging Laboratory, Department of Radiology, University of California, San Francisco
  • 7/90-9/97
    Faculty Member, Graduate Group in Biophysics, University of California, San Francisco
  • 7/92-6/95
    Assistant Professor, Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco
  • 7/95-6/02
    Associate Adjunct Professor, Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco
  • 9/97-present
    Faculty Member, Bioengineering Graduate Group, University of California, San Francisco and University of California, Berkeley
  • 1/98-present
    Faculty Member, Breast Oncology Program, UCSF Cancer Center
  • 7/02-present
    Professor in Residence, Magnetic Resonance Science Center, Department of Radiology, University of California, San Francisco
  • 2/04-present
    Director, Magnetic Resonance Science Center, Dept. of Radiology, UCSF

Selected Publications

  1. Wang J, Azziz A, Fan B, Malkov S, Klifa C, Newitt D, Yitta S, Hylton N, Kerlikowske K, Shepherd JA. Agreement of mammographic measures of volumetric breast density to MRI. PLoS One. 2013; 8(12):e81653.
    View on PubMed
  2. Wisner DJ, Hwang ES, Chang CB, Tso HH, Joe BN, Lessing JN, Lu Y, Hylton NM. Features of Occult Invasion in Biopsy-Proven DCIS at Breast MRI. Breast J. 2013 Nov; 19(6):650-8.
    View on PubMed
  3. Dorgan JF, Klifa C, Deshmukh S, Egleston BL, Shepherd JA, Kwiterovich PO, Van Horn L, Snetselaar LG, Stevens VJ, Robson AM, Lasser NL, Hylton NM. Menstrual and reproductive characteristics and breast density in young women. Cancer Causes Control. 2013 Nov; 24(11):1973-83.
    View on PubMed
  4. Ojeda-Fournier H, de Guzman J, Hylton N. Breast magnetic resonance imaging for monitoring response to therapy. Magn Reson Imaging Clin N Am. 2013 Aug; 21(3):533-46.
    View on PubMed
  5. Bolouri MS, Elias SG, Wisner DJ, Behr SC, Hawkins RA, Suzuki SA, Banfield KS, Joe BN, Hylton NM. Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging. Radiology. 2013 Nov; 269(2):354-61.
    View on PubMed
  6. Mukhtar RA, Yau C, Rosen M, Tandon VJ. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12):3823-30.
    View on PubMed
  7. Yitta S, Joe BN, Wisner DJ, Price ER, Hylton NM. Recognizing artifacts and optimizing breast MRI at 1.5 and 3 T. AJR Am J Roentgenol. 2013 Jun; 200(6):W673-82.
    View on PubMed
  8. Lehman CD, Blume JD, DeMartini WB, Hylton NM, Herman B, Schnall MD. Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers. AJR Am J Roentgenol. 2013 Jun; 200(6):W683-9.
    View on PubMed
  9. Mahoney ME, Gordon EJ, Rao JY, Jin Y, Hylton N, Love SM. Intraductal therapy of ductal carcinoma in situ: a presurgery study. Clin Breast Cancer. 2013 Aug; 13(4):280-6.
    View on PubMed
  10. Jones EF, Sinha SP, Newitt DC, Klifa C, Kornak J, Park CC, Hylton NM. MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy. PLoS One. 2013; 8(5):e61969.
    View on PubMed
  11. Wilmes LJ, McLaughlin RL, Newitt DC, Singer L, Sinha SP, Proctor E, Wisner DJ, Saritas EU, Kornak J, Shankaranarayanan A, Banerjee S, Jones EF, Joe BN, Hylton NM. High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response. Acad Radiol. 2013 May; 20(5):581-9.
    View on PubMed
  12. De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013 May 15; 119(10):1776-83.
    View on PubMed
  13. Hylton N. MR imaging for the prediction of breast cancer response to neoadjuvant chemotherapy. Radiology. 2013 Jan; 266(1):367.
    View on PubMed
  14. Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012 Jun; 263(3):663-72.
    View on PubMed
  15. Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol. 2012 Jun; 13(6):e240-8.
    View on PubMed
  16. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9.
    View on PubMed
  17. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62.
    View on PubMed
  18. Singer L, Wilmes LJ, Saritas EU, Shankaranarayanan A, Proctor E, Wisner DJ, Chang B, Joe BN, Nishimura DG, Hylton NM. High-resolution diffusion-weighted magnetic resonance imaging in patients with locally advanced breast cancer. Acad Radiol. 2012 May; 19(5):526-34.
    View on PubMed
  19. Partridge SC, Singer L, Sun R, Wilmes LJ, Klifa CS, Lehman CD, Hylton NM. Diffusion-weighted MRI: influence of intravoxel fat signal and breast density on breast tumor conspicuity and apparent diffusion coefficient measurements. Magn Reson Imaging. 2011 Nov; 29(9):1215-21.
    View on PubMed
  20. Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast. 2011 Dec; 20(6):529-33.
    View on PubMed

Go to UCSF Profiles, powered by CTSI